Ascendis Health’s share price slumped to an all-time low on Tuesday, as efforts to stabilise the debt-laden business suffered a blow after discussions for a proposed sale of its crown jewel in Cyprus collapsed.

CEO Mark Sardi said the health and wellness company, which has a market capitalisation of about R1.174bn, had called off the talks to sell  its Remedica business and instead resolved to engage with lenders about restructuring its debt before disposing of the Cyprus-based pharmaceutical maker. 

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now